Recent developments in the use of pre-and probiotics for irritable bowel syndrome

Saunjoo L. Yoon, Baharak Moshiree, Oliver Grundmann

Research output: Contribution to journalArticle

Abstract

Irritable bowel syndrome (IBS) is a functional bowel disorder (FBD) with a high prevalence that significantly impacts patients' quality of life. Given the lack of a biomarker for IBS, pharmacological treatment approaches have remained symptom-oriented and often do not provide sufficient relief. The use of prebiotics, such as oligosaccharides, lactulose and probiotic bacterial strains, has been advocated as beneficial in relieving symptoms of IBS. This review focuses on recent developments in the use of prebiotics and probiotics for the treatment of IBS. Well-designed clinical trials have been conducted that support the use of probiotic bacterial strains, mainly Lactobacillus, Bifidobacterium and Streptococcus, to reduce abdominal pain, bloating and flatulence in patients with IBS. Both prebiotics and probiotics have shown none or only mild adverse effects and should be recommended as an adjuvant therapy for patients with IBS to improve their quality of life.

Original languageEnglish
Pages (from-to)237-241
Number of pages5
JournalEuropean Gastroenterology and Hepatology Review
Volume7
Issue number4
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Irritable Bowel Syndrome
Probiotics
Prebiotics
Quality of Life
Flatulence
Lactulose
Bifidobacterium
Lactobacillus
Streptococcus
Oligosaccharides
Abdominal Pain
Therapeutics
Biomarkers
Clinical Trials
Pharmacology

Keywords

  • Bifidobacterium
  • Clinical trials
  • Irritable bowel syndrome
  • Prebiotics
  • Probiotics
  • Quality of life

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Recent developments in the use of pre-and probiotics for irritable bowel syndrome. / Yoon, Saunjoo L.; Moshiree, Baharak; Grundmann, Oliver.

In: European Gastroenterology and Hepatology Review, Vol. 7, No. 4, 01.01.2012, p. 237-241.

Research output: Contribution to journalArticle

Yoon, Saunjoo L. ; Moshiree, Baharak ; Grundmann, Oliver. / Recent developments in the use of pre-and probiotics for irritable bowel syndrome. In: European Gastroenterology and Hepatology Review. 2012 ; Vol. 7, No. 4. pp. 237-241.
@article{e9be2293b9194f82ac607ef82d2f6724,
title = "Recent developments in the use of pre-and probiotics for irritable bowel syndrome",
abstract = "Irritable bowel syndrome (IBS) is a functional bowel disorder (FBD) with a high prevalence that significantly impacts patients' quality of life. Given the lack of a biomarker for IBS, pharmacological treatment approaches have remained symptom-oriented and often do not provide sufficient relief. The use of prebiotics, such as oligosaccharides, lactulose and probiotic bacterial strains, has been advocated as beneficial in relieving symptoms of IBS. This review focuses on recent developments in the use of prebiotics and probiotics for the treatment of IBS. Well-designed clinical trials have been conducted that support the use of probiotic bacterial strains, mainly Lactobacillus, Bifidobacterium and Streptococcus, to reduce abdominal pain, bloating and flatulence in patients with IBS. Both prebiotics and probiotics have shown none or only mild adverse effects and should be recommended as an adjuvant therapy for patients with IBS to improve their quality of life.",
keywords = "Bifidobacterium, Clinical trials, Irritable bowel syndrome, Prebiotics, Probiotics, Quality of life",
author = "Yoon, {Saunjoo L.} and Baharak Moshiree and Oliver Grundmann",
year = "2012",
month = "1",
day = "1",
language = "English",
volume = "7",
pages = "237--241",
journal = "European Gastroenterology and Hepatology Review",
issn = "1758-3799",
publisher = "Touch Briefings",
number = "4",

}

TY - JOUR

T1 - Recent developments in the use of pre-and probiotics for irritable bowel syndrome

AU - Yoon, Saunjoo L.

AU - Moshiree, Baharak

AU - Grundmann, Oliver

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Irritable bowel syndrome (IBS) is a functional bowel disorder (FBD) with a high prevalence that significantly impacts patients' quality of life. Given the lack of a biomarker for IBS, pharmacological treatment approaches have remained symptom-oriented and often do not provide sufficient relief. The use of prebiotics, such as oligosaccharides, lactulose and probiotic bacterial strains, has been advocated as beneficial in relieving symptoms of IBS. This review focuses on recent developments in the use of prebiotics and probiotics for the treatment of IBS. Well-designed clinical trials have been conducted that support the use of probiotic bacterial strains, mainly Lactobacillus, Bifidobacterium and Streptococcus, to reduce abdominal pain, bloating and flatulence in patients with IBS. Both prebiotics and probiotics have shown none or only mild adverse effects and should be recommended as an adjuvant therapy for patients with IBS to improve their quality of life.

AB - Irritable bowel syndrome (IBS) is a functional bowel disorder (FBD) with a high prevalence that significantly impacts patients' quality of life. Given the lack of a biomarker for IBS, pharmacological treatment approaches have remained symptom-oriented and often do not provide sufficient relief. The use of prebiotics, such as oligosaccharides, lactulose and probiotic bacterial strains, has been advocated as beneficial in relieving symptoms of IBS. This review focuses on recent developments in the use of prebiotics and probiotics for the treatment of IBS. Well-designed clinical trials have been conducted that support the use of probiotic bacterial strains, mainly Lactobacillus, Bifidobacterium and Streptococcus, to reduce abdominal pain, bloating and flatulence in patients with IBS. Both prebiotics and probiotics have shown none or only mild adverse effects and should be recommended as an adjuvant therapy for patients with IBS to improve their quality of life.

KW - Bifidobacterium

KW - Clinical trials

KW - Irritable bowel syndrome

KW - Prebiotics

KW - Probiotics

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=84875246137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875246137&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84875246137

VL - 7

SP - 237

EP - 241

JO - European Gastroenterology and Hepatology Review

JF - European Gastroenterology and Hepatology Review

SN - 1758-3799

IS - 4

ER -